Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.

BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.

Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.

HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.

Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.

Breakthrough Alzheimer updates: UK adaptive platform trial tests repurposed drugs, new phase 2/3 therapies advance, and sleep disruption emerges as a treatable risk factor.

Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.

UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.